Newron's ralfinamide fails for neuropathic pain
This article was originally published in Scrip
Executive Summary
Newron Pharmaceuticals' analgesic candidate ralfinamide has failed to show a benefit over placebo in the Phase IIb/III SERENA study in patients with moderate neuropathic low back pain (NLBP), top-line data have revealed.